Osteoporosis trial favored denosumab on bone measures and reported adverse reactions
A trial in postmenopausal women found differences in bone density and reported reactions, while sex-hormone results did not differ significantly.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Denosumab recipients had higher bone mineral density and different bone-marker levels than zoledronic acid recipients during follow-up. Reported adverse reactions were also less frequent with denosumab. The measured sex hormone levels did not differ significantly between groups. These results describe bone measurements and reported reactions; the abstract does not establish a difference in fracture prevention.
The abstract does not report the size of the bone-density differences, the types or severity of adverse reactions, or fracture outcomes. Those omissions limit conclusions about overall clinical benefit and safety.
What researchers found
Reported adverse reactions
Denosumab versus zoledronic acid, both with standard care, over 1 year; the between-group difference was statistically significant.
What the trial measured
This abstract-based comparison randomly assigned women with postmenopausal osteoporosis to the drug groups. Researchers measured bone density at several sites, blood markers related to bone metabolism, sex hormones, and adverse reactions.
What remains unresolved
The hormone comparisons were not statistically significant, so the abstract cannot establish that the drugs have equivalent hormonal effects. Similarly, favorable bone measurements do not by themselves demonstrate fewer fractures.
The original publication
Efficacy and Safety of Denosumab and Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis-A Comparative Study of Bone Metabolism, Bone Density, and Sex Hormone Levels.
Tang H, Chen J, Fan X
J Appl Toxicol · 2026
- PubMed ID
- 41139405
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.